Chesley Taft & Associates LLC Has $5.20 Million Stake in AbbVie Inc. $ABBV

Chesley Taft & Associates LLC raised its position in AbbVie Inc. (NYSE:ABBV) by 18.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 22,751 shares of the company’s stock after buying an additional 3,501 shares during the quarter. Chesley Taft & Associates LLC’s holdings in AbbVie were worth $5,198,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC boosted its holdings in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after buying an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. raised its holdings in shares of AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after buying an additional 789 shares in the last quarter. Grantham Mayo Van Otterloo & Co. LLC lifted its position in shares of AbbVie by 16.1% during the 2nd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 6,792 shares of the company’s stock worth $1,261,000 after buying an additional 940 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its position in shares of AbbVie by 4.5% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 261,036 shares of the company’s stock worth $48,453,000 after buying an additional 11,322 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

ABBV has been the topic of a number of recent analyst reports. William Blair reiterated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Finally, Piper Sandler increased their price objective on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Company outlook and dividend expectations — Analysts and commentators highlight AbbVie’s strong 2026 guidance and the likelihood of future dividend increases, driven by cash flow from Humira/Imbruvica/oncology and growth in the dermatology portfolio; that narrative supports income investors and dividend yield buyers. AbbVie: Strong 2026 Outlook, Expect Dividend Increases
• Positive Sentiment: Clinical and real‑world data boost dermatology franchise — AbbVie announced new clinical and real‑world evidence for risankizumab (psoriasis/psoriatic arthritis) and upadacitinib (atopic dermatitis), plus Phase‑3 data for vitiligo and alopecia areata to be presented at AAD 2026. Strong safety/efficacy reads can support durable revenue and reduce investor uncertainty around launches. AbbVie to Highlight New Clinical and Real-World Evidence…
• Positive Sentiment: Analyst estimate tweak — Erste Group modestly raised its FY2027 EPS estimate for AbbVie, signaling incremental confidence in earnings power (small change but supportive vs. downside fears). MarketBeat AbbVie Profile
• Neutral Sentiment: Allergan Aesthetics (AbbVie unit) scientific presence — Allergan is presenting multiple evidence‑based posters and product positioning (JUVÉDERM, HA injectables) at AMWC, reinforcing aesthetics growth and brand leadership but with limited immediate revenue impact. Allergan Aesthetics Reinforces Scientific Differentiation…
• Neutral Sentiment: Dividend yield framing for investors — Retail‑focused pieces (The Motley Fool) calculate how many ABBV shares generate targeted dividend income; useful for income investors but not an earnings catalyst. Here’s How Many Shares of AbbVie (ABBV) Stock You’d Need…
• Negative Sentiment: Recent price weakness & value debate — Coverage noting recent share‑price declines and questions about valuation may pressure sentiment in the short term; headline focus on near‑term multiple compression can spur selling even as fundamentals are debated. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?

AbbVie Trading Down 0.8%

AbbVie stock opened at $209.46 on Friday. The stock has a 50-day moving average price of $221.96 and a two-hundred day moving average price of $224.62. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The company has a market capitalization of $370.37 billion, a PE ratio of 88.76, a P/E/G ratio of 0.73 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same period in the previous year, the business posted $2.16 earnings per share. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is presently 293.22%.

Insider Activity at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.25% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.